Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05036135




Registration number
NCT05036135
Ethics application status
Date submitted
16/08/2021
Date registered
5/09/2021
Date last updated
23/08/2024

Titles & IDs
Public title
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Scientific title
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
Secondary ID [1] 0 0
AV-101-002
Universal Trial Number (UTN)
Trial acronym
IMPAHCT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AV-101
Treatment: Drugs - Placebo

Experimental: AV-101 10 mg -

Experimental: AV-101 35 mg -

Experimental: AV-101 70 mg -

Placebo comparator: Placebo -


Treatment: Drugs: AV-101
AV-101 (imatinib) administered via dry powder inhalation

Treatment: Drugs: Placebo
Placebo administered via dry powder inhalation
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Phase 2b: Change from Baseline in Pulmonary Vascular Resistance (PVR)
Timepoint [1] 0 0
24 weeks
Primary outcome [2] 0 0
Phase 3: Change from Baseline in Six Minute Walk Distance (6MWD)
Timepoint [2] 0 0
24 weeks
Secondary outcome [1] 0 0
Phase 2b: Change from Baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP)
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
Phase 2b: Change from Baseline in Six Minute Walk Distance (6MWD)
Timepoint [2] 0 0
24 weeks
Secondary outcome [3] 0 0
Phase 2b: Time to Clinical Worsening
Timepoint [3] 0 0
24 weeks
Secondary outcome [4] 0 0
Phase 2b: Proportion of Subjects with Improvement in WHO Functional Class
Timepoint [4] 0 0
24 weeks
Secondary outcome [5] 0 0
Phase 2b: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score
Timepoint [5] 0 0
24 weeks
Secondary outcome [6] 0 0
Phase 2b: Change from Baseline in Health-Related Quality of Life emPHasis-10 Questionnaire Score
Timepoint [6] 0 0
24 weeks
Secondary outcome [7] 0 0
Phase 3: Change from Baseline in NT-proBNP
Timepoint [7] 0 0
24 weeks
Secondary outcome [8] 0 0
Phase 3: Time to Clinical Worsening
Timepoint [8] 0 0
24 weeks
Secondary outcome [9] 0 0
Phase 3: Proportion of Subjects with Improvement in WHO Functional Class
Timepoint [9] 0 0
24 weeks
Secondary outcome [10] 0 0
Phase 3: Change from Baseline in Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Risk Score
Timepoint [10] 0 0
24 weeks
Secondary outcome [11] 0 0
Phase 3: Change from Baseline in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire Score
Timepoint [11] 0 0
24 weeks

Eligibility
Key inclusion criteria
Key Inclusion Criteria

* PAH belonging to one of the subgroups:

1. I/HPAH, PAH-CTD,
2. PAH due to drugs and/or toxins/chemicals (having been in the care of the investigator for at least one year with no relapses of drug or toxin/chemical abuse),
3. HIV associated or
4. PAH due to repaired congenital heart disease (at least 1 year since repair)
* World Health Organization (WHO) Functional Class II, III or IV symptoms
* Stable concomitant background therapy of at least one PAH approved medications
* Able to walk a distance of at least 100 m but no more than 475 m during the Screening 6-minute walk tests.

Key
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Pulmonary hypertension (PH) belonging to Groups 2 to 5
* A history of left-sided heart disease
* Pregnant or breast-feeding females

Additional criteria may apply, per protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/08/2024
Sample size
Target
Accrual to date
Final
202
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord West
Recruitment hospital [3] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [4] 0 0
Westmead Hospital - Westmead
Recruitment hospital [5] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [6] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [7] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [8] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [9] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2138 - Concord West
Recruitment postcode(s) [3] 0 0
2747 - Kingswood
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment postcode(s) [5] 0 0
4575 - Birtinya
Recruitment postcode(s) [6] 0 0
4032 - Chermside
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment postcode(s) [8] 0 0
5000 - Adelaide
Recruitment postcode(s) [9] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Mexico
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Córdoba
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Austria
State/province [28] 0 0
Vienna
Country [29] 0 0
Belgium
State/province [29] 0 0
Brussels
Country [30] 0 0
Belgium
State/province [30] 0 0
Leuven
Country [31] 0 0
Brazil
State/province [31] 0 0
Porto Alegre
Country [32] 0 0
Brazil
State/province [32] 0 0
São Paulo
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Santiago
Country [37] 0 0
China
State/province [37] 0 0
Beijing
Country [38] 0 0
China
State/province [38] 0 0
Chongqing
Country [39] 0 0
China
State/province [39] 0 0
Guangdong
Country [40] 0 0
China
State/province [40] 0 0
Hunan
Country [41] 0 0
China
State/province [41] 0 0
Kunming
Country [42] 0 0
China
State/province [42] 0 0
Lanzhou
Country [43] 0 0
China
State/province [43] 0 0
Nanjing
Country [44] 0 0
China
State/province [44] 0 0
Shanghai
Country [45] 0 0
China
State/province [45] 0 0
Tianjin
Country [46] 0 0
Czechia
State/province [46] 0 0
Praha
Country [47] 0 0
France
State/province [47] 0 0
Cedex
Country [48] 0 0
France
State/province [48] 0 0
Bron
Country [49] 0 0
France
State/province [49] 0 0
Marseille
Country [50] 0 0
France
State/province [50] 0 0
Montpellier
Country [51] 0 0
France
State/province [51] 0 0
Strasbourg
Country [52] 0 0
Germany
State/province [52] 0 0
Dresden
Country [53] 0 0
Germany
State/province [53] 0 0
Giesen
Country [54] 0 0
Germany
State/province [54] 0 0
Heidelberg
Country [55] 0 0
Germany
State/province [55] 0 0
München
Country [56] 0 0
Greece
State/province [56] 0 0
Athens
Country [57] 0 0
Greece
State/province [57] 0 0
Kallithéa
Country [58] 0 0
Greece
State/province [58] 0 0
Thessaloníki
Country [59] 0 0
Israel
State/province [59] 0 0
Haifa
Country [60] 0 0
Israel
State/province [60] 0 0
Jerusalem
Country [61] 0 0
Israel
State/province [61] 0 0
Tel Aviv
Country [62] 0 0
Italy
State/province [62] 0 0
Foggia
Country [63] 0 0
Italy
State/province [63] 0 0
Milan
Country [64] 0 0
Italy
State/province [64] 0 0
Monza
Country [65] 0 0
Italy
State/province [65] 0 0
Napoli
Country [66] 0 0
Italy
State/province [66] 0 0
Palermo
Country [67] 0 0
Italy
State/province [67] 0 0
Pavia
Country [68] 0 0
Italy
State/province [68] 0 0
Rome
Country [69] 0 0
Latvia
State/province [69] 0 0
Riga
Country [70] 0 0
Mexico
State/province [70] 0 0
Jalisco
Country [71] 0 0
Mexico
State/province [71] 0 0
Nuevo León
Country [72] 0 0
Mexico
State/province [72] 0 0
Mexico City
Country [73] 0 0
Mexico
State/province [73] 0 0
Monterrey
Country [74] 0 0
Netherlands
State/province [74] 0 0
Amsterdam
Country [75] 0 0
Poland
State/province [75] 0 0
Krakow
Country [76] 0 0
Poland
State/province [76] 0 0
Poznan
Country [77] 0 0
Poland
State/province [77] 0 0
Wroclaw
Country [78] 0 0
Poland
State/province [78] 0 0
Lódz
Country [79] 0 0
Portugal
State/province [79] 0 0
Almada
Country [80] 0 0
Portugal
State/province [80] 0 0
Lisboa
Country [81] 0 0
Portugal
State/province [81] 0 0
Porto
Country [82] 0 0
Puerto Rico
State/province [82] 0 0
Guaynabo
Country [83] 0 0
Singapore
State/province [83] 0 0
Singapore
Country [84] 0 0
South Africa
State/province [84] 0 0
Johannesburg
Country [85] 0 0
Spain
State/province [85] 0 0
Barcelona
Country [86] 0 0
Spain
State/province [86] 0 0
Las Palmas de Gran Canaria
Country [87] 0 0
Spain
State/province [87] 0 0
Madrid
Country [88] 0 0
Spain
State/province [88] 0 0
Málaga
Country [89] 0 0
Spain
State/province [89] 0 0
Salamanca
Country [90] 0 0
Spain
State/province [90] 0 0
Santander
Country [91] 0 0
Spain
State/province [91] 0 0
Toledo
Country [92] 0 0
Sweden
State/province [92] 0 0
Umeå
Country [93] 0 0
United Kingdom
State/province [93] 0 0
England
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Glasgow
Country [95] 0 0
United Kingdom
State/province [95] 0 0
London
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Newcastle

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Aerovate Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk distance (6MWD) after 24 weeks of treatment.
Trial website
https://clinicaltrials.gov/study/NCT05036135
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Toll Free Number
Address 0 0
Country 0 0
Phone 0 0
(888) 373-8110
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05036135